Testicular Lumps: What Is Worth Checking, and What Happens Next

Testicular cancer is rare, extremely curable, and concentrated almost entirely in men young enough to assume cancer is not something that happens to them. That combination produces a specific failure: men find something, wait, and arrive later than they needed to. The median delay between a man noticing a change and seeing a doctor, in one cohort, was thirty days.

Who actually gets it

Testicular cancer accounts for about 0.5 percent of new cancer diagnoses in American men, with an age-adjusted incidence of 6.0 per 100,000 per year. Lifetime risk is around 1 in 250. Lifetime risk of dying from it is around 1 in 5,000. In the United Kingdom there are roughly 2,300 new cases and about 70 deaths each year.

What makes it distinctive is the age distribution.

Median age at diagnosis is 33. Three quarters of cases occur before 45. This is the most common solid cancer in young men, and incidence in the United States has roughly doubled over the past four decades for reasons nobody has established.

Survival is exceptional and stage-dependent.

The gap between 99 and 72 is what this article is about. It is not a gap between living and dying for most men, but it is the difference between an orchiectomy and surveillance, and multiple cycles of chemotherapy with the long-term consequences described below.

Risk factors, with the figures attached:

Undescended testis is the strongest. Overall risk is around three to four times higher in men with a history of cryptorchidism. In unilateral cases the risk is 6.3 times higher in the undescended testicle and still 1.7 times higher in the normally descended one, which is why about one in four cancers in these men arises on the unaffected side. Risk is two to six times higher when correction was late or never performed. About 10 percent of men with testicular cancer have a history of cryptorchidism.

Family history. Risk is roughly four to five times higher if a father was affected and eight to nine times higher if a brother was.

Previous testicular cancer. About 3 to 4 percent of men cured in one testicle will later develop cancer in the other.

HIV. A pooled analysis across three cohorts and 282,268 HIV-positive men gave an odds ratio of 1.71 (1.51 to 1.93).

Ethnicity. Incidence is 7.1 per 100,000 in white men, 5.4 in Hispanic men and 1.7 in African American men.

What it presents as

The classic presentation is a painless lump or swelling in one testicle, found by the man himself. But painless is not universal: roughly a third of patients report a dull ache, and about 10 percent have acute pain, usually from bleeding into the tumour.

Other presentations worth knowing. A sense of heaviness or firmness in the scrotum without a discrete lump. Gynaecomastia, breast tissue development, from tumours producing hCG. And in about 5 percent of men, the first symptoms are of spread rather than of the primary: persistent low back pain from enlarged retroperitoneal lymph nodes, breathlessness, cough, or chest pain.

The delay data are the most useful thing here. In a cohort of 60 men with a median age of 26, the median patient delay from noticing a change to presenting was 30 days, with a range up to a full year. Median doctor delay was 7 days. Of the men who noticed a change, 54 percent were initially misdiagnosed, and in those cases doctor delay rose from a median of 1 day to 14.

Two things follow. If you find something, the wait is yours to eliminate. And if you are told it is an infection and it does not resolve on antibiotics, go back, because that is the specific pathway on which weeks get lost.

What else a scrotal lump can be

Most scrotal lumps are not cancer. The examination features below are what a clinician uses to sort them, and they are worth knowing because they tell you how urgently to act.

The single most useful distinction for a man examining himself is whether the lump is part of the testicle or attached to something behind it. Cysts and spermatoceles sit on the epididymis and can be felt as separate from the smooth ovoid of the testis. A tumour is of the testis. If you cannot tell, that is precisely what an ultrasound is for.

The one that cannot wait

Torsion is not a variant of the lump problem. It is a different emergency that happens to occur in the same organ, and it is worth separating clearly because the time pressure is unlike anything else here.

The spermatic cord twists, cutting off blood supply. Salvage rates fall sharply with time: approximately 90 percent if detorsion is performed within six hours of symptom onset, around 50 percent after twelve hours, and roughly 10 percent after twenty-four. Another source puts salvage near 100 percent within six hours and describes it as rare beyond a day.

It is most common between ages 12 and 18 but can occur at any age. Sudden severe testicular pain, particularly with nausea or vomiting, means emergency department now, not a GP appointment tomorrow. The classic examination signs, an absent cremasteric reflex and a high-riding testis, are helpful when present but are explicitly described as unreliable, so their absence does not rule it out.

Why screening is not recommended

The US Preventive Services Task Force recommends against screening for testicular cancer in adolescent or adult men, at Grade D. This surprises people, so it is worth setting out the reasoning rather than just the conclusion.

The argument is not that finding it early does not matter. It is that there is inadequate evidence that systematic screening by self-examination or clinician examination detects cancer at more curable stages than simply presenting when something is noticed, and that given low incidence and cure rates above 90 percent regardless of stage, screening is unlikely to produce a net benefit once false positives and unnecessary procedures are counted. The Task Force’s stated conclusion is moderate certainty of no net benefit.

Not everyone agrees, and this is a genuine difference of professional opinion rather than one body being behind. The European Association of Urology lists “encourage self-examination” as a recommendation, graded weak. The American Cancer Society sits between the two: it does not recommend regular self-exams for all men, because they have not been studied enough, but it advises men to be aware and to see a doctor immediately on finding a lump, and says men with risk factors such as an undescended testicle, a prior germ cell tumour or a family history should seriously consider monthly self-examination.

The practical synthesis, which all three positions support: nobody is telling you to perform a monthly ritual, and everybody is telling you that a lump you have noticed warrants an appointment this week.

What happens after you present

The pathway is unusually standardised.

Ultrasound. High-frequency scrotal ultrasound is the first test and is reported as approaching 100 percent sensitivity for testicular cancer. Size matters for interpretation: virtually all lesions under 3 mm are benign, as are 87 percent of those under 5 mm and 70 percent of those under 10 mm.

Tumour markers. Alpha-fetoprotein, beta-hCG and LDH are measured before surgery and again afterwards. Up to 90 percent of non-seminomatous tumours have an elevated AFP or beta-hCG at diagnosis, with 39 percent showing both. AFP is not produced by pure seminoma, so a raised AFP in an apparent seminoma raises the possibility of an unrecognised non-seminomatous component. The half-lives matter for follow-up: AFP 5 to 7 days, beta-hCG 1 to 3 days.

Surgery, through the groin rather than the scrotum. This is the one piece of the pathway that surprises people. A tumour is never biopsied through the scrotum, because doing so risks seeding cancer into scrotal tissue and a different lymphatic drainage basin. A retrospective comparison found local recurrence in 2.9 percent after a transscrotal approach against 0.4 percent after the standard inguinal one. The operation is a radical inguinal orchiectomy, with the spermatic cord divided at the internal inguinal ring.

Fertility, and what comes later

Fertility is frequently already affected before any treatment begins. In a series of 2,315 men with testicular germ cell tumours, only 50.9 percent were normozoospermic at diagnosis and 5.0 percent were azoospermic, with median total sperm counts four times lower than fertile controls.

Because of that, sperm banking before treatment carries a strong recommendation in the European guideline, and it should be discussed with every man, not only those who currently want children. It costs a single appointment and it is not recoverable afterwards.

The outlook is nonetheless reasonably good. Roughly 70 percent of men go on to father children after treatment. After platinum-based chemotherapy, the calculated chance of recovering spermatogenesis was 48 percent at two years and 80 percent at five.

Late effects are real and are the reason stage at diagnosis matters even when survival is near-universal. Cardiac events are increased around 2.5-fold in men who received treatment compared with those managed by surveillance alone. Overall second malignancy risk is about 1.8 times that of the general population, rising to 2.9 times in men who had both radiotherapy and chemotherapy. Testosterone replacement was required by 12.0 percent of men after cisplatin-based chemotherapy against 8.2 percent after surgery alone.

None of which is an argument for fear. It is an argument for the specific, unglamorous behaviour this whole article points at: if something in your scrotum has changed, get it scanned. The scan is quick, it is not invasive, and in the large majority of cases it will tell you that what you found is a cyst.

This article is for information only and is not medical advice. Sudden severe testicular pain, particularly with nausea or vomiting, needs emergency care immediately rather than a routine appointment. Any new lump in a testicle should be assessed by a clinician.